Načítá se...
Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in...
Uloženo v:
| Vydáno v: | Pharmacol Res Perspect |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947217/ https://ncbi.nlm.nih.gov/pubmed/33694304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.723 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|